- Home
- LNKB vs ADAP Comparison
LNKB vs ADAP Comparison
Compare LNKB & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNKB
- ADAP
- Stock Information
- Founded
- LNKB 2018
- ADAP 2008
- Country
- LNKB United States
- ADAP United Kingdom
- Employees
- LNKB N/A
- ADAP N/A
- Industry
- LNKB
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- LNKB
- ADAP Health Care
- Exchange
- LNKB Nasdaq
- ADAP Nasdaq
- Market Cap
- LNKB 263.0M
- ADAP 212.3M
- IPO Year
- LNKB N/A
- ADAP 2015
- Fundamental
- Price
- LNKB $7.16
- ADAP $0.59
- Analyst Decision
- LNKB Hold
- ADAP Strong Buy
- Analyst Count
- LNKB 1
- ADAP 4
- Target Price
- LNKB $7.50
- ADAP $3.16
- AVG Volume (30 Days)
- LNKB 42.9K
- ADAP 2.0M
- Earning Date
- LNKB 10-28-2024
- ADAP 11-13-2024
- Dividend Yield
- LNKB 4.19%
- ADAP N/A
- EPS Growth
- LNKB 61.51
- ADAP N/A
- EPS
- LNKB 0.17
- ADAP N/A
- Revenue
- LNKB $86,138,000.00
- ADAP $175,041,000.00
- Revenue This Year
- LNKB N/A
- ADAP $180.15
- Revenue Next Year
- LNKB $9.49
- ADAP N/A
- P/E Ratio
- LNKB $42.64
- ADAP N/A
- Revenue Growth
- LNKB 151.51
- ADAP 146.27
- 52 Week Low
- LNKB $5.86
- ADAP $0.42
- 52 Week High
- LNKB $8.29
- ADAP $2.05
- Technical
- Relative Strength Index (RSI)
- LNKB 55.74
- ADAP 26.22
- Support Level
- LNKB $7.27
- ADAP $0.75
- Resistance Level
- LNKB $7.59
- ADAP $0.83
- Average True Range (ATR)
- LNKB 0.30
- ADAP 0.07
- MACD
- LNKB 0.01
- ADAP -0.01
- Stochastic Oscillator
- LNKB 52.32
- ADAP 2.36
About LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.